WO2015152772A1 - Method of producing a therapeutic wipe - Google Patents

Method of producing a therapeutic wipe Download PDF

Info

Publication number
WO2015152772A1
WO2015152772A1 PCT/RU2015/000207 RU2015000207W WO2015152772A1 WO 2015152772 A1 WO2015152772 A1 WO 2015152772A1 RU 2015000207 W RU2015000207 W RU 2015000207W WO 2015152772 A1 WO2015152772 A1 WO 2015152772A1
Authority
WO
WIPO (PCT)
Prior art keywords
active substance
mixture
textile material
dimethyl sulfoxide
polymer base
Prior art date
Application number
PCT/RU2015/000207
Other languages
French (fr)
Russian (ru)
Inventor
Наталия Дмитриевна ОЛТАРЖЕВСКАЯ
Герман Евсеевич КРИЧЕВСКИЙ
Мария Анатольевна КОРОВИНА
Лариса Борисовна САВИЛОВА
Original Assignee
Общество с ограниченной ответственностью "КОЛЕТЕКС"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "КОЛЕТЕКС" filed Critical Общество с ограниченной ответственностью "КОЛЕТЕКС"
Publication of WO2015152772A1 publication Critical patent/WO2015152772A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments

Definitions

  • the invention relates to medicine, namely to pharmaceutical compositions for providing targeted delivery of drugs.
  • a disadvantage of the known method of treatment is that it requires complication of the technological process (in addition to the operation of adding a solution of dimexide in the polymer, a printing operation is performed by the composition with the polymer and the drug (after drying).
  • a method of obtaining a therapeutic composition for applying it on textile material comprising preparing a polymer base by introducing a biopolymer with constant stirring in distilled water, keeping for 12-24 hours at a temperature of 22-30 ° C, the introduction of drugs, mixing the mixture for 45-90 minutes on a low-speed mixer.
  • the disadvantage of this method is the need to measure the viscosity of the composition 2 times - after its preparation and after sterilization (in packaged form), when the packaging of the sample of the finished product for measuring viscosity is opened, after which it loses sterility and is not suitable for use.
  • the whole batch from which the test sample was taken will be unsuitable for use, as it does not correspond viscosity index; It is additionally not possible to re-sterilize these products either from the point of view of technology compliance and compliance with permits, or from the point of view of the impossibility of achieving the desired viscosity indices, in addition, this leads to large economic losses due to the need to release new batches of products and dispose of previously released ones.
  • the presence of particles with a size of 20-250 nm at least 90% is mandatory in the composition, which greatly limits the choice of polymers, because The characteristics of the natural polymers used do not always correspond to the indicated values.
  • the task set by the authors is to eliminate these shortcomings, expand the range of medicines and dietary supplements, provide the possibility of varying their concentration, which will determine their use in the treatment of various diseases, will ensure rapid transformation of the process and its economic feasibility.
  • the polymer composition with the active substance must be applied to the textile material through a mesh template with a mesh size of 200 to 450 ⁇ m before creating a continuous polymer material on the front surface of the textile material layer without penetration on the wrong side.
  • the method is as follows.
  • the active substance is a single drug, a biologically active substance or a mixture of drugs and biologically active substances, their dosage is determined by a therapeutically effective amount depending on medical requirements.
  • the finished polymer composition is applied through a mesh template with a mesh size of 200-450 ⁇ m using a doctor blade on a textile material with a raw material composition that contains at least 50% cellulose fibers.
  • a polymer base is prepared, then 5% by mass of ⁇ -aminocaproic acid and 2% by mass of nettles are introduced, after which the mixture is mixed again.
  • Non-woven material (cotton / viscose - 50/50) was used as textile material, and a mesh pattern was used with a mesh size of 350 ⁇ m. Sterilization was carried out at a dose of 15 kGy.
  • a polymer base is prepared, then 5% by mass, ⁇ -aminocaproic acid, 2% by mass, nettle and 2% by mass, chamomile are added, after which the mixture is mixed again.
  • a textile material used non-woven material (cotton / viscose - 50/50), and the mesh pattern was used with a mesh size of 350 microns. Sterilization was carried out at a dose of 15 kGy.
  • a polymer base is prepared, then 5% by mass of ⁇ -aminocaproic acid and 2% by mass of lidocaine hydrochloride are introduced, after which the mixture is mixed again.
  • Non-woven material cotton / viscose - 50/50
  • a mesh pattern was used with a mesh size of 350 ⁇ m. Sterilization was carried out at a dose of 15 kGy.
  • a polymer base is prepared, then 0.9% by mass, mexidol, 5% by mass, dimethyl sulfoxide, 0.4% by mass, hydrocortisone acetate and 0.3% by mass, actovegin are introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 4.5% by weight of propolis is introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 10.0% by weight of metronidazole is introduced, after which the mixture is mixed again.
  • a textile material used knitted material polyester / cotton fiber - 35/65
  • the mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 20.0% by mass of metronidazole and 2% by mass of dimethyl sulfoxide are introduced, after which the mixture is again mixed.
  • a textile material used knitted material As a textile material used knitted material
  • a polymer base is prepared, then 30.0% by weight is added. dimethyl sulfoxide, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.9% by weight is added. deoxyribonucleate, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.9% by mass of deoxyribonucleate and 1% by mass of blueberries are introduced, after which the mixture is stirred again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.9% by weight is added. deoxyribonucleate and 2% by weight, lidocaine hydrochloride, after which the mixture is again stirred.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 5.0% by weight are added. 5-fluorouracil, after which the mixture is again stirred.
  • Non-woven material (cotton / viscose - 40/60) was used as textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.000005% by mass, interleukin-1 beta, is introduced, after which the mixture is mixed again.
  • Non-woven material cotton / viscose - 50/50
  • a mesh pattern was used with a mesh size of 200 ⁇ m. Sterilization was carried out at a dose of 15 kGy.
  • a polymer base is prepared, then 0.000005%) by mass, interleukin-1 beta and 2% by mass are added. dimethyl sulfoxide, after which the mixture is again stirred.
  • Non-woven material cotton / viscose 40/60 was used as textile material, and a mesh pattern was used with a mesh size of 200 ⁇ m. Sterilization was carried out at a dose of 15 kGy.
  • a polymer base is prepared, then 0.4% by weight is added.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.4% by mass of hydrocortisone acetate and 2% by mass of lidocaine hydrochloride are introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 20.0% by weight of urea is introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • Example 19 Analogously to example 1, a polymer base is prepared, then 20.0% by mass of urea and 2% by mass of dimethyl sulfoxide are introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 0.9% by mass, dioxidine 2% by mass, lidocaine hydrochloride are introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 325 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 3.5% by weight of furagin is introduced, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 325 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • a polymer base is prepared, then 2.5% by mass, chlorhexidine 2% by mass, lidocaine hydrochloride are introduced, after which the mixture is mixed again.
  • a textile material used knitted material As a textile material used knitted material
  • a polymer base is prepared, then 4.5% by mass of methyluracil, 2% by mass of dimethyl sulfoxide and 0.4% by mass of hydrocortisone acetate are added, after which the mixture is mixed again.
  • Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 ⁇ m. Sterilization was carried out at a dose of 25 kGy.
  • the proposed method is technological, easy to implement, including, if necessary, varying drugs, allows you to get medical wipes with a wide range of drugs, regardless of their solubility, use, including biologically active substances, to achieve, prolong the action of the introduced active substances, it is economical to use therapeutic composition due to its unilateral application, to contribute to the closure of the wound, preventing its injury, while treating.

Abstract

The invention relates to medicine, and specifically to pharmaceutical compositions for providing targeted delivery of medicinal preparations. Producing a therapeutic wipe includes preparing a polymer base containing an alginic acid salt, and introducing an active substance which is proposed to consist of a substance selected from the proposed group in a therapeutically effective amount. Mixing this mixture in a low-speed mixer, applying the resulting composition to a textile material containing cellulose fibers, and drying same, wherein it is recommended to use a textile material comprised of at least 50% cellulose fibers. The composition of the polymer with the active substance should be applied to the textile material through a mesh template with a cell spacing of between 200 and 450 micrometers, until a continuous polymer layer is formed on the front surface of the textile material without seeping through to the reverse side. The use, according to the proposed method, of a composition having a viscosity of 25.0-50.0 Pa·s, with ϒ =3 с-1, provides for the necessary technological viscosity. In addition, it is proposed to use the textile material in sheets, and to apply the mixture of polymer base and active substance through the mesh template by means of a trowel-like device. It is preferable to use a mixture of polymer base and active substance having a viscosity of 25.0-50.0 Pa·s, with ϒ =3 с-1. The method allows for broadening the assortment of medicinal agents and biologically active additives, and for providing for varied concentrations thereof, thus allowing same to be used in the treatment of various diseases, while allowing for rapidly transforming the technological process and the economic feasibility thereof.

Description

Способ получения лечебной салфетки  A method of obtaining a medical napkin
Изобретение относится к медицине, а именно к фармацевтическим композициям для обеспечения адресной доставки лекарственных препаратов. The invention relates to medicine, namely to pharmaceutical compositions for providing targeted delivery of drugs.
Известен способ получения лечебной салфетки (Патент РФ N° 2465921, МПК A61F 13/00, A61L 15/12, A61L 15/28 публ. 2011г.) включающий проведение плюсования текстильного материала в растворе лекарственного средства с последующей сушкой на воздухе.  There is a method of obtaining a medical napkin (RF Patent N ° 2465921, IPC A61F 13/00, A61L 15/12, A61L 15/28 publ. 2011) including the addition of textile material in a solution of the drug, followed by drying in air.
Недостатком известного способа лечения является то, что он требует усложнения технологического процесса (дополнительно к операции плюсования раствором димексида в полимере проводится (после сушки) операция печати композицией с полимером и лекарством).  A disadvantage of the known method of treatment is that it requires complication of the technological process (in addition to the operation of adding a solution of dimexide in the polymer, a printing operation is performed by the composition with the polymer and the drug (after drying).
Наиболее близким к предлагаемому является способ получения лечебной композиции для нанесения ее на текстильный материл (Патент РФ N° 2400250, МПК А61К 9/70, А61К 47/36, А61К 47/38 публ. 2010г.), включающий приготовление полимерной основы путем введения биополимера при постоянном перемешивании в дистиллированную воду, выдерживание в течение 12-24 часов при температуре 22-30°С, введение лекарственных препаратов, перемешивание смеси в течение 45-90 минут на тихоходной мешалке.  Closest to the proposed is a method of obtaining a therapeutic composition for applying it on textile material (RF Patent N ° 2400250, IPC A61K 9/70, A61K 47/36, A61K 47/38 publ. 2010), comprising preparing a polymer base by introducing a biopolymer with constant stirring in distilled water, keeping for 12-24 hours at a temperature of 22-30 ° C, the introduction of drugs, mixing the mixture for 45-90 minutes on a low-speed mixer.
Недостатком этого способа является необходимость измерения вязкости композиции 2 раза - после ее приготовления и после стерилизации (в упакованном виде), когда упаковку образца готового продукта для измерения вязкости вскрывают, после чего он теряет стерильность и является не пригодным для использования. Естественно, что не пригодной для использования будет являться и вся партия, из которой был взят образец для испытаний, как не соответствующая показателю вязкости; перестерилизовать эту продукцию дополнительно не представляется возможным ни с точки зрения соблюдения технологии и соответствия разрешительным документам, ни с точки зрения невозможности достижения нужных показателей вязкости, кроме того это приводит к большим экономическим потерям из-за необходимости выпуска новых партий продукции и утилизации выпущенных ранее. Кроме того, согласно прототипу обязательным в композиции является наличие частиц размером 20-250 нм не менее 90%, что сильно ограничивает выбор полимеров, т.к. характеристики используемых природных полимеров не всегда соответствуют указанным значениям. The disadvantage of this method is the need to measure the viscosity of the composition 2 times - after its preparation and after sterilization (in packaged form), when the packaging of the sample of the finished product for measuring viscosity is opened, after which it loses sterility and is not suitable for use. Naturally, the whole batch from which the test sample was taken will be unsuitable for use, as it does not correspond viscosity index; It is additionally not possible to re-sterilize these products either from the point of view of technology compliance and compliance with permits, or from the point of view of the impossibility of achieving the desired viscosity indices, in addition, this leads to large economic losses due to the need to release new batches of products and dispose of previously released ones. In addition, according to the prototype, the presence of particles with a size of 20-250 nm at least 90% is mandatory in the composition, which greatly limits the choice of polymers, because The characteristics of the natural polymers used do not always correspond to the indicated values.
Задача, поставленная авторами, - устранить указанные недостатки, расширить ассортимент лекарственных средств и биологически активных добавок, обеспечить возможность варьирования их концентрации, что обусловит их применение при лечении различных заболеваний, позволит обеспечить быструю трансформацию технологического процесса и его экономическую целесообразность.  The task set by the authors is to eliminate these shortcomings, expand the range of medicines and dietary supplements, provide the possibility of varying their concentration, which will determine their use in the treatment of various diseases, will ensure rapid transformation of the process and its economic feasibility.
Для решения поставленной задачи при изготовлении лечебной салфетки, включающем приготовление полимерной основы, содержащей соли альгиновой кислоты, введение активного вещества в терапевтически эффективном количестве, перемешивание смеси в тихоходной мешалке, нанесение полученной композиции на текстильный материал, содержащий целлюлозные волокна, сушку, предложено использовать текстильный материал, содержащий не менее 50% целлюлозных волокон. При этом композицию полимера с активным веществом надо наносить на текстильный материал через сетчатый шаблон с размером ячейки от 200 до 450 мкм до создания на лицевой поверхности текстильного материала сплошного полимерного слоя без проникновения на изнаночную сторону. To solve the problem in the manufacture of therapeutic napkins, including the preparation of a polymer base containing salts of alginic acid, the introduction of the active substance in a therapeutically effective amount, mixing the mixture in a low-speed mixer, applying the resulting composition to a textile material containing cellulose fibers, drying, it is proposed to use a textile material containing at least 50% cellulose fibers. In this case, the polymer composition with the active substance must be applied to the textile material through a mesh template with a mesh size of 200 to 450 μm before creating a continuous polymer material on the front surface of the textile material layer without penetration on the wrong side.
Использование согласно предполагаемому способу композиции с вязкостью 25,0-50,0 Па-с при γ = 3 с" 'обеспечивает нужную технологическую вязкость. The use according to the proposed method of a composition with a viscosity of 25.0-50.0 Pa-s at γ = 3 s " provides the desired process viscosity.
Кроме того, предложено использовать текстильный материал в полотнах, а смесь полимерной основы с активным веществом наносить через сетчатый шаблон с помощью ракли. Преимущественно следует использовать смесь полимерной основы с активным веществом с вязкостью 25,0-50,0 Па-с при γ = 3 с' \ In addition, it is proposed to use textile material in canvases, and apply the mixture of the polymer base with the active substance through a mesh pattern using a squeegee. Advantageously, a mixture of a polymer base with an active substance with a viscosity of 25.0-50.0 Pa-s at γ = 3 s ' \
В качестве активного вещества предлагается использовать  It is proposed to use as an active substance
- ε-аминокапроновую кислоту;  - ε-aminocaproic acid;
- крапиву;  - nettles;
- смесь ε-аминокапроновой кислоты и крапивы;  - a mixture of ε-aminocaproic acid and nettle;
- смесь ε-аминокапроновой кислоты, крапивы и ромашки;  - a mixture of ε-aminocaproic acid, nettle and chamomile;
- смесь ε-аминокапроновой кислоты и лидокаина гидрохлорида; - a mixture of ε-aminocaproic acid and lidocaine hydrochloride;
- смесь мексидола, диметилсульфоксида, гидрокортизона ацетата и актовегина; - a mixture of Mexidol, dimethyl sulfoxide, hydrocortisone acetate and Actovegin;
- прополис;  - propolis;
- метронидазол;  - metronidazole;
- диметилсульфоксид;  - dimethyl sulfoxide;
- смесь метронидазола и диметилсульфоксида;  - a mixture of metronidazole and dimethyl sulfoxide;
- дезоксирибонуклеат натрия;  - sodium deoxyribonucleate;
- смесь дезоксирибонуклеата натрия и черники;  - a mixture of sodium deoxyribonucleate and blueberries;
- смесь дерзоксирибонуклеата натрия и лидокаина гидрохлорида; - 5-фторурацил;  - a mixture of sodium dersoxyribonucleate and lidocaine hydrochloride; - 5-fluorouracil;
- интерлейкин-1 бета;  - interleukin-1 beta;
- смесь диметилсульфоксида и интерлейкин-1 бета;  - a mixture of dimethyl sulfoxide and interleukin-1 beta;
- смесь гидрокортизона ацетата и диметилсульфоксида; - гидрокортизона ацетата и лидокаина гидрохлорида; - a mixture of hydrocortisone acetate and dimethyl sulfoxide; - hydrocortisone acetate and lidocaine hydrochloride;
- мочевину;  urea
- смесь мочевины и диметилсульфоксида;  - a mixture of urea and dimethyl sulfoxide;
- смесь диоксидина и лидокаина гидрохлорида;  - a mixture of dioxidine and lidocaine hydrochloride;
- фурагин;  - furagin;
- хлоргексидин;  - chlorhexidine;
- смесь метилурацила, диметилсульфоксида и гидрокортизона ацетата.  - a mixture of methyluracil, dimethyl sulfoxide and hydrocortisone acetate.
Способ осуществляется следующим образом.  The method is as follows.
В емкость с водой засыпают альгинат натрия и заливают дистиллированной воды и тщательно перемешивают на тихоходной мешалке, затем вводят активное вещество в терапевтически эффективном количестве. Активное вещество представляет собой одно лекарственное средство, биологически активное вещество или смесь лекарственных средств и биологически активных веществ, дозировка их определяется терапевтически эффективным количеством в зависимости от медицинских требований.  Sodium alginate is poured into a container with water and filled with distilled water and thoroughly mixed on a slow-moving mixer, then the active substance is introduced in a therapeutically effective amount. The active substance is a single drug, a biologically active substance or a mixture of drugs and biologically active substances, their dosage is determined by a therapeutically effective amount depending on medical requirements.
Затем готовую полимерную композицию наносят через сетчатый шаблон с размером ячеек 200-450 мкм с помощью ракли на текстильный материал с сырьевым составом, в котором содержится не менее 50% целлюлозных волокон.  Then, the finished polymer composition is applied through a mesh template with a mesh size of 200-450 μm using a doctor blade on a textile material with a raw material composition that contains at least 50% cellulose fibers.
Разработанная технологическая документация и большой производственный опыт позволяют в каждом конкретном случае выбрать текстильный материал с указанным вложением целлюлозных волокон и полимерную композицию определенной вязкости с набором активных веществ, обеспечивающих при определенной силе прижима и угле заточки ракли (при ручном или автоматическом производстве) нанесение равномерного сплошного полимерного слоя на лицевой поверхности текстильного материала, без его проникновения на изнаночную сторону полотна. Полотна с нанесенной композицией сушат при комнатной температуре, режут на салфетки, например, размером 6x10 см, упаковывают, стерилизуют в дозе 15-25 кГр. The developed technological documentation and extensive production experience make it possible in each case to choose a textile material with the indicated cellulosic fiber attachment and a polymer composition of a certain viscosity with a set of active substances that provide a uniform continuous polymer coating with a certain pressure and sharpening angle of the squeegee (with manual or automatic production) layer on the front the surface of the textile material, without its penetration on the wrong side of the fabric. Fabrics coated with the composition are dried at room temperature, cut into napkins, for example, 6x10 cm in size, packaged, sterilized in a dose of 15-25 kGy.
Пример 1.  Example 1
В емкость с водой объемом 150 мл засыпают 7 г альгината натрия и заливают 93 мл дистиллированной воды и тщательно перемешивают на тихоходной мешалке, затем вводят 5% по масс, ε-аминокапроновой кислоты, после чего смесь снова перемешивают. Затем готовую полимерную композицию наносят с помощью ракли на текстильный трикотажный материал с сырьевым составом 7 g of sodium alginate are poured into a 150 ml water tank and 93 ml of distilled water are added and mixed thoroughly on a slow-moving mixer, then 5% by mass of ε-aminocaproic acid is introduced, after which the mixture is mixed again. Then the finished polymer composition is applied using a squeegee on a textile knitted material with a raw material composition
(полиэфирное/хлопковискозное волокно - 35/65) через сетчатый шаблон с размером ячеек 450 мкм, так, чтобы полимерный слой не проникал на изнанку, полотна сушат при комнатной температуре, режут на салфетки размером 6x10 см, упаковывают, стерилизуют в дозе 15 кГр. (polyester / cotton fiber - 35/65) through a mesh template with a mesh size of 450 μm, so that the polymer layer does not penetrate the wrong side, the webs are dried at room temperature, cut into 6x10 cm wipes, packaged, sterilized at a dose of 15 kGy.
Пример 2.  Example 2
Аналогично примеру 1 готовят полимерную основу, затем вводят 5% по масс, ε-аминокапроновой кислоты и 2% по масс, крапивы, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материал (хлопковое/вискозное - 50/50), а сетчатый шаблон применили с размером ячеек 350 мкм. Стерилизацию провели в дозе 15 кГр.  Analogously to example 1, a polymer base is prepared, then 5% by mass of ε-aminocaproic acid and 2% by mass of nettles are introduced, after which the mixture is mixed again. Non-woven material (cotton / viscose - 50/50) was used as textile material, and a mesh pattern was used with a mesh size of 350 μm. Sterilization was carried out at a dose of 15 kGy.
Пример 3.  Example 3
Аналогично примеру 1 готовят полимерную основу, затем вводят 5% по масс, ε-аминокапроновой кислоты, 2% по масс, крапивы и 2% по масс, ромашки, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материал (хлопковое/вискозное - 50/50), а сетчатый шаблон применили с размером ячеек 350 мкм. Стерилизацию провели в дозе 15 кГр. Analogously to example 1, a polymer base is prepared, then 5% by mass, ε-aminocaproic acid, 2% by mass, nettle and 2% by mass, chamomile are added, after which the mixture is mixed again. As a textile material used non-woven material (cotton / viscose - 50/50), and the mesh pattern was used with a mesh size of 350 microns. Sterilization was carried out at a dose of 15 kGy.
Пример 4.  Example 4
Аналогично примеру 1 готовят полимерную основу, затем вводят 5% по масс, ε-аминокапроновой кислоты, и 2% по масс, лидокаина гидрохлорида, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материал (хлопковое/вискозное - 50/50), а сетчатый шаблон применили с размером ячеек 350 мкм. Стерилизацию провели в дозе 15 кГр.  Analogously to example 1, a polymer base is prepared, then 5% by mass of ε-aminocaproic acid and 2% by mass of lidocaine hydrochloride are introduced, after which the mixture is mixed again. Non-woven material (cotton / viscose - 50/50) was used as textile material, and a mesh pattern was used with a mesh size of 350 μm. Sterilization was carried out at a dose of 15 kGy.
Пример 5.  Example 5
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,9% по масс, мексидола, 5% по масс, диметилсульфоксида, 0,4% по масс, гидрокортизона ацетата и 0,3% по масс, актовегина, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.9% by mass, mexidol, 5% by mass, dimethyl sulfoxide, 0.4% by mass, hydrocortisone acetate and 0.3% by mass, actovegin are introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 6.  Example 6
Аналогично примеру 1 готовят полимерную основу, затем вводят 4,5% по масс, прополиса, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 4.5% by weight of propolis is introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 7.  Example 7
Аналогично примеру 1 готовят полимерную основу, затем вводят 10,0% по масс, метронидазола, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр. Analogously to example 1, a polymer base is prepared, then 10.0% by weight of metronidazole is introduced, after which the mixture is mixed again. As a textile material used knitted material (polyester / cotton fiber - 35/65), and the mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 8.  Example 8
Аналогично примеру 1 готовят полимерную основу, затем вводят 20,0% по масс, метронидазола и 2% по масс, диметилсульфоксида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал Analogously to example 1, a polymer base is prepared, then 20.0% by mass of metronidazole and 2% by mass of dimethyl sulfoxide are introduced, after which the mixture is again mixed. As a textile material used knitted material
(полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр. (polyester / cotton fiber - 35/65), and the mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 9.  Example 9
Аналогично примеру 1 готовят полимерную основу, затем вводят 30,0% по масс. диметилсульфоксида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 30.0% by weight is added. dimethyl sulfoxide, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 10.  Example 10
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,9% по масс. дезоксирибонуклеата, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.9% by weight is added. deoxyribonucleate, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 11.  Example 11
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,9% по масс, дезоксирибонуклеата и 1% по масс, черники, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр. Analogously to example 1, a polymer base is prepared, then 0.9% by mass of deoxyribonucleate and 1% by mass of blueberries are introduced, after which the mixture is stirred again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 12.  Example 12
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,9% по масс. дезоксирибонуклеата и 2% по масс, лидокаина гидрохлорида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65) , а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.9% by weight is added. deoxyribonucleate and 2% by weight, lidocaine hydrochloride, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 13.  Example 13
Аналогично примеру 1 готовят полимерную основу, затем вводят 5,0% по масс. 5-фторурацила, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материл (хлопковое/вискозное - 40/60), а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 5.0% by weight are added. 5-fluorouracil, after which the mixture is again stirred. Non-woven material (cotton / viscose - 40/60) was used as textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 14.  Example 14
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,000005% по масс, интерлейкин-1 бета, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материл (хлопковое/вискозное - 50/50) , а сетчатый шаблон применили с размером ячеек 200 мкм. Стерилизацию провели в дозе 15 кГр.  Analogously to example 1, a polymer base is prepared, then 0.000005% by mass, interleukin-1 beta, is introduced, after which the mixture is mixed again. Non-woven material (cotton / viscose - 50/50) was used as textile material, and a mesh pattern was used with a mesh size of 200 μm. Sterilization was carried out at a dose of 15 kGy.
Пример 15.  Example 15
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,000005%) по масс, интерлейкин-1 бета и 2% по масс. диметилсульфоксида, после чего смесь снова перемешивают. В качестве текстильного материал использовали нетканый материал (хлопковое/вискозное - 40/60), а сетчатый шаблон применили с размером ячеек 200 мкм. Стерилизацию провели в дозе 15 кГр. Analogously to example 1, a polymer base is prepared, then 0.000005%) by mass, interleukin-1 beta and 2% by mass are added. dimethyl sulfoxide, after which the mixture is again stirred. Non-woven material (cotton / viscose 40/60) was used as textile material, and a mesh pattern was used with a mesh size of 200 μm. Sterilization was carried out at a dose of 15 kGy.
Пример 16.  Example 16
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,4% по масс. гидрокортизона ацетата и 2% по масс, диметилсульфоксида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.4% by weight is added. hydrocortisone acetate and 2% by weight of dimethyl sulfoxide, after which the mixture is again stirred. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 17.  Example 17
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,4% по масс, гидрокортизона ацетата и 2% по масс, лидокаина гидрохлорида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.4% by mass of hydrocortisone acetate and 2% by mass of lidocaine hydrochloride are introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 18.  Example 18
Аналогично примеру 1 готовят полимерную основу, затем вводят 20,0% по масс, мочевины, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 20.0% by weight of urea is introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 19. Аналогично примеру 1 готовят полимерную основу, затем вводят 20,0% по масс, мочевины и 2% по масс, диметилсульфоксида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 250 мкм. Стерилизацию провели в дозе 25 кГр. Example 19 Analogously to example 1, a polymer base is prepared, then 20.0% by mass of urea and 2% by mass of dimethyl sulfoxide are introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 250 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 20.  Example 20
Аналогично примеру 1 готовят полимерную основу, затем вводят 0,9% по масс, диоксидина 2% по масс, лидокаина гидрохлорида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 325 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 0.9% by mass, dioxidine 2% by mass, lidocaine hydrochloride are introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 325 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 21.  Example 21
Аналогично примеру 1 готовят полимерную основу, затем вводят 3,5% по масс, фурагина, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 325 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 3.5% by weight of furagin is introduced, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 325 μm. Sterilization was carried out at a dose of 25 kGy.
Пример 22.  Example 22
Аналогично примеру 1 готовят полимерную основу, затем вводят 2,5% по масс, хлоргексидина 2% по масс, лидокаина гидрохлорида, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал Analogously to example 1, a polymer base is prepared, then 2.5% by mass, chlorhexidine 2% by mass, lidocaine hydrochloride are introduced, after which the mixture is mixed again. As a textile material used knitted material
(полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 325 мкм. Стерилизацию провели в дозе 25 кГр. Пример 23. (polyester / cotton fiber 35/65), and a mesh pattern was used with a mesh size of 325 μm. Sterilization was carried out at a dose of 25 kGy. Example 23
Аналогично примеру 1 готовят полимерную основу, затем вводят 4,5% по масс, метилурацила, 2% по масс, диметилсульфоксида и 0,4% по масс, гидрокортизона ацетата, после чего смесь снова перемешивают. В качестве текстильного материал использовали трикотажный материал (полиэфирное/хлопковискозное волокно - 35/65), а сетчатый шаблон применили с размером ячеек 450 мкм. Стерилизацию провели в дозе 25 кГр.  Analogously to example 1, a polymer base is prepared, then 4.5% by mass of methyluracil, 2% by mass of dimethyl sulfoxide and 0.4% by mass of hydrocortisone acetate are added, after which the mixture is mixed again. Knitted material (polyester / cotton fiber 35/65) was used as a textile material, and a mesh pattern was used with a mesh size of 450 μm. Sterilization was carried out at a dose of 25 kGy.
Предложенный способ технологичен, легко осуществим, в том числе при необходимости варьирования лекарственных средств, позволяет получать лечебные салфетки с широким спектром лекарственных препаратов независимо от их растворимости, использовать, в том числе биологически активные вещества, добиваться, пролонгации действия введенных активных веществ, экономично использовать применяемую лечебную композицию за счет одностороннего ее нанесения, способствовать закрытию раны, предотвращая ее травмирование, при одновременном лечении.  The proposed method is technological, easy to implement, including, if necessary, varying drugs, allows you to get medical wipes with a wide range of drugs, regardless of their solubility, use, including biologically active substances, to achieve, prolong the action of the introduced active substances, it is economical to use therapeutic composition due to its unilateral application, to contribute to the closure of the wound, preventing its injury, while treating.

Claims

Формула изобретения Claim
1. Способ получения лечебной салфетки, включающий приготовление полимерной основы, содержащей соли альгиновой кислоты, введение активного вещества в терапевтически эффективном количестве, перемешивание смеси в тихоходной мешалке, нанесение полученной композиции на текстильный материал, содержащий целлюлозные волокна, сушку, отличающийся тем, что используют текстильный материал, содержащий не менее 50% целлюлозных волокон, а композицию полимера с активным веществом наносят на текстильный материал через сетчатый шаблон с размером ячейки от 200 до 450 мкм до создания на лицевой поверхности текстильного материала сплошного полимерного слоя без проникновения на изнаночную сторону. 1. A method for producing a medicinal napkin, including preparing a polymer base containing alginic acid salts, introducing an active substance in a therapeutically effective amount, stirring the mixture in a low-speed mixer, applying the resulting composition to a textile material containing cellulose fibers, drying, characterized in that textile a material containing at least 50% cellulose fibers, and a polymer composition with an active substance is applied to the textile material through a mesh template with a cell size of 200 to 450 microns until a continuous polymer layer is created on the front surface of the textile material without penetrating onto the reverse side.
2. Способ по п.1 отличающийся тем, что используется текстильный материал в полотнах. 2. The method according to claim 1, characterized in that textile material is used in the canvases.
3. Способ по п.1 отличающийся тем, что в смесь полимерной основы с активным веществом наносят через сетчатый шаблон с помощью ракли. 3. The method according to claim 1, characterized in that it is applied to the mixture of the polymer base and the active substance through a mesh template using a squeegee.
4. Способ по п.1 отличающийся тем, используют смесь полимерной основы с активным веществом с вязкостью 25,0-50,0 Па-с при γ = 3 с" \ 4. The method according to claim 1, characterized in that a mixture of a polymer base with an active substance with a viscosity of 25.0-50.0 Pa-s at γ = 3 s " \
5. Способ по п.1 отличающийся тем, что в качестве активного вещества используют ε-аминокапроновую кислоту. 5. The method according to claim 1, characterized in that ε-aminocaproic acid is used as the active substance.
6. Способ по п.1 отличающийся тем, что в качестве активного вещества используют крапиву. 6. The method according to claim 1, characterized in that nettle is used as the active substance.
7. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь ε-аминокапроновой кислоты и крапивы. 7. The method according to claim 1, characterized in that a mixture of ε-aminocaproic acid and nettle is used as the active substance.
8. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь ε-аминокапроновой кислоты, крапивы и ромашки. 8. The method according to claim 1, characterized in that as an active substances use a mixture of ε-aminocaproic acid, nettle and chamomile.
9. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь ε-аминокапроновой кислоты и лидокаина гидрохлорида. 9. The method according to claim 1, characterized in that a mixture of ε-aminocaproic acid and lidocaine hydrochloride is used as the active substance.
10. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь мексидола, диметилсульфоксида, гидрокортизона ацетата и актовегина. 10. The method according to claim 1, characterized in that a mixture of Mexidol, dimethyl sulfoxide, hydrocortisone acetate and Actovegin is used as the active substance.
11 Способ по п.1 отличающийся тем, что в качестве активного вещества используют прополис. 11 The method according to claim 1, characterized in that propolis is used as the active substance.
12. Способ по п.1 отличающийся тем, что в качестве активного вещества используют метронидазол. 12. The method according to claim 1, characterized in that metronidazole is used as the active substance.
13. Способ по п.1 отличающийся тем, что в качестве активного вещества используют диметилсульфоксид. 13. The method according to claim 1, characterized in that dimethyl sulfoxide is used as the active substance.
14. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь метронидазола и диметилсульфоксида. 14. The method according to claim 1, characterized in that a mixture of metronidazole and dimethyl sulfoxide is used as the active substance.
15. Способ по п.1 отличающийся тем, что в качестве активного вещества используют дезоксирибонуклеат натрия. 15. The method according to claim 1, characterized in that sodium deoxyribonucleate is used as the active substance.
16. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь дезоксирибонуклеата натрия и черники. 16. The method according to claim 1, characterized in that a mixture of sodium deoxyribonucleate and blueberries is used as the active substance.
17. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь дерзоксирибонуклеата натрия и лидокаина гидрохлорида. 17. The method according to claim 1, characterized in that a mixture of sodium deroxyribonucleate and lidocaine hydrochloride is used as the active substance.
18. Способ по п.1 отличающийся тем, что в качестве активного вещества используют 5-фторурацил. 18. The method according to claim 1, characterized in that 5-fluorouracil is used as the active substance.
19. Способ по п.1 отличающийся тем, что в качестве активного вещества используют интерлейкин-1 бета. 19. The method according to claim 1, characterized in that interleukin-1 beta is used as the active substance.
20. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь диметилсульфоксида и интерлейкин-1 бета. 20. The method according to claim 1, characterized in that as an active The substances use a mixture of dimethyl sulfoxide and interleukin-1 beta.
21. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь гидрокортизона ацетата и диметилсульфоксида. 21. The method according to claim 1, characterized in that a mixture of hydrocortisone acetate and dimethyl sulfoxide is used as the active substance.
22. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь гидрокортизона ацетата и лидокаина гидрохлорида. 22. The method according to claim 1, characterized in that a mixture of hydrocortisone acetate and lidocaine hydrochloride is used as the active substance.
23. Способ по п.1 отличающийся тем, что в качестве активного вещества используют мочевину. 23. The method according to claim 1, characterized in that urea is used as the active substance.
24. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь мочевины и диметилсульфоксида. 24. The method according to claim 1, characterized in that a mixture of urea and dimethyl sulfoxide is used as the active substance.
25. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь диоксидина и лидокаина гидрохлорида. 25. The method according to claim 1, characterized in that a mixture of dioxidine and lidocaine hydrochloride is used as the active substance.
26. Способ по п.1 отличающийся тем, что в качестве активного вещества используют фурагин. 26. The method according to claim 1, characterized in that furagin is used as the active substance.
27. Способ по п.1 отличающийся тем, что в качестве активного вещества используют хлоргексидин. 27. The method according to claim 1, characterized in that chlorhexidine is used as the active substance.
28. Способ по п.1 отличающийся тем, что в качестве активного вещества используют смесь метилурацила, диметилсульфоксида и гидрокортизона ацетата. 28. The method according to claim 1, characterized in that a mixture of methyluracil, dimethyl sulfoxide and hydrocortisone acetate is used as the active substance.
PCT/RU2015/000207 2014-04-01 2015-03-31 Method of producing a therapeutic wipe WO2015152772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014112520/15A RU2539381C1 (en) 2014-04-01 2014-04-01 Method for producing therapeutic tissue
RU2014112520 2014-04-01

Publications (1)

Publication Number Publication Date
WO2015152772A1 true WO2015152772A1 (en) 2015-10-08

Family

ID=53288507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2015/000207 WO2015152772A1 (en) 2014-04-01 2015-03-31 Method of producing a therapeutic wipe

Country Status (2)

Country Link
RU (1) RU2539381C1 (en)
WO (1) WO2015152772A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2714384C1 (en) * 2018-12-20 2020-02-17 Акционерное общество "Научно-исследовательский институт конструкционных материалов на основе графита "НИИграфит" Method of producing carbon non-woven fibrous material for medicine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2193896C2 (en) * 2001-02-08 2002-12-10 Гаврилюк Борис Карпович Covering for wounds
RU2209074C2 (en) * 2001-08-29 2003-07-27 Общество с ограниченной ответственностью "Олимп" Method for treating burns
US20060222616A1 (en) * 2003-08-28 2006-10-05 Tadashi Yoneda Cosmetic composition comprising a and a lipopeptide
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2010105634A1 (en) * 2009-03-17 2010-09-23 United Technologies Ut Ag Use of interleukin-1 beta in cosmetic compositions and methods thereof
RU2400250C1 (en) * 2009-01-14 2010-09-27 Общество с ограниченной ответственностью "НПО Текстильпрогресс ИА" (ООО "НПО Текстильпрогресс ИА") Method of obtaining medicinal composition for its application on textile material
RU2409371C1 (en) * 2009-08-17 2011-01-20 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Analgesic, haemostatic and wound healing agent
RU2483755C1 (en) * 2012-04-26 2013-06-10 Общество с ограниченной ответственностью "КОЛЕТЕКС" Wound tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU9739U1 (en) * 1998-09-28 1999-05-16 Олтаржевская Наталия Дмитриевна MULTILAYERED TREATMENT-BASED MEDICAL MATERIAL
RU2247580C2 (en) * 2003-02-04 2005-03-10 Болдырев Сергей Николаевич Layered material with prolonged therapeutical effect for treating wounds, burns, and bedsores as well as for providing first medical aid

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2193896C2 (en) * 2001-02-08 2002-12-10 Гаврилюк Борис Карпович Covering for wounds
RU2209074C2 (en) * 2001-08-29 2003-07-27 Общество с ограниченной ответственностью "Олимп" Method for treating burns
US20060222616A1 (en) * 2003-08-28 2006-10-05 Tadashi Yoneda Cosmetic composition comprising a and a lipopeptide
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
RU2400250C1 (en) * 2009-01-14 2010-09-27 Общество с ограниченной ответственностью "НПО Текстильпрогресс ИА" (ООО "НПО Текстильпрогресс ИА") Method of obtaining medicinal composition for its application on textile material
WO2010105634A1 (en) * 2009-03-17 2010-09-23 United Technologies Ut Ag Use of interleukin-1 beta in cosmetic compositions and methods thereof
RU2409371C1 (en) * 2009-08-17 2011-01-20 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Analgesic, haemostatic and wound healing agent
RU2483755C1 (en) * 2012-04-26 2013-06-10 Общество с ограниченной ответственностью "КОЛЕТЕКС" Wound tissue

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIBKOVA V. A.: "«Razrabotka tekhnologii polucheniia profilakticheskikh i lechebnykh tekstilnykh materialov dlia primeneniia v kosmetologii i dermatologii»", AVTOREFERAT DISSERTATSII NA SOISKANIE UCHENOI STEPENI KANDIDATA TEKHNICHESKIKH NAUK, M., 2005, pages 1 - 16 *
KOROVINA M. A.: "«Razrabotka metodologii i tekhnologii sozdaniia lechebnykh tekstilnykh i gidrogelevykh applikatsii dlia napravlennoi mestnoi dostavki lekarstv pri luchevoi terapii onkologicheskikh zabolevanii (teoriia i praktika)»", AVTOREFERAT DISSERTATSII NA SOISKANIE UCHENOI STEPENI DOKTORA TEKHNICHESKIKH NAUK, M., 2011, pages 1 - 41 *

Also Published As

Publication number Publication date
RU2539381C1 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
AU2006329661B2 (en) Hemostatic material
US20120101457A1 (en) Needle device
WO2002005789A2 (en) Solution-, dispersion- or emulsion-producing film dermatics
CN103520764A (en) Functional dressing, and preparation method and application thereof
Wang et al. Self-assembling in situ gel based on lyotropic liquid crystals containing VEGF for tissue regeneration
KR20090014693A (en) Skin care sheet using nano scale nonwoven and process therefore
CN102078636A (en) Hydrogel dressing containing recombinant human epidermal growth factor and preparation method and application thereof
CN103596560A (en) Sheet and liquid combination systems for dermal drug delivery
PL239827B1 (en) Dressing unwoven fabric and method for producing the dressing unwoven fabric
CN104188939B (en) A kind of local topical paster agent containing lidocaine or its pharmaceutical salts
WO2014042250A1 (en) Drug-containing ultrafine fiber and utilization thereof
CN106390179B (en) A kind of polyurethane sponge dressing and preparation method thereof with the hemostatic function that prevents adhesion
CN102697755A (en) Novel levo-carnitine hydrogel patch and preparation method thereof
RU2539381C1 (en) Method for producing therapeutic tissue
KR20210021535A (en) Electrospun fiber containing nanodispersion and its use for wound healing
JPS6263512A (en) Base for hydrous gel patch
DE202006004622U1 (en) Wound healing pad comprises a perforated hollow profile, a hollow fiber or a film labyrinth through which an injected medicinal liquid or gas is distributed onto an overlying absorbent textile layer
CN107412286A (en) A kind of preparation method for being used to treat arthralgic external plaster
CN103976942B (en) Canker sore gel and preparation method thereof
RU2483755C1 (en) Wound tissue
US20220241204A1 (en) Topical time release delivery using layered biopolymer
CN106687153A (en) Combination cellulose material and method of making and using same
JP2021116305A (en) Micro-spicule composition to control its shape and method for producing the same
CN106139228A (en) Medical alginic acid zinc functional dressings and preparation method thereof
RU2400250C1 (en) Method of obtaining medicinal composition for its application on textile material

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773936

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15773936

Country of ref document: EP

Kind code of ref document: A1